Online inquiry

IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11430MR)

This product GTTS-WQ11430MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) infection research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11430MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5523MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ162MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ9259MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ8994MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ10373MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ6392MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ2123MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ12771MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW